JCCC Research Seminar featuring David Nathanson
Development of brain penetrant EGFR inhibitors for malignant glioma
- Date: February 13, 2020 12:00 PM - 1:00 PM
- Location: 53-105 CHS
10833 Le Conte Ave.
Los Angeles, California 90095
David Nathanson, Ph.D.
Department of Molecular and Medical Pharmacology
Dr. David Nathanson’s laboratory focuses on glioblastoma (GBM), the most lethal form of brain cancer. The Nathanson lab has specific interest in investigating altered signal transduction networks and the interplay with GBM metabolism, with a strong emphasis on metabolic phenotyping of specific oncogenic signals using non-invasive positron emission tomography (PET). In addition, they are interested in understanding the mechanisms of resistance to targeted therapies in GBM, including intrinsic adaptive signaling and the role of tumor heterogeneity. Their ultimate goal is to develop new strategies 1) to use metabolic PET to non-invasively measure oncogene activity for drug development/dosing and 2) to predict and exploit tumor adaptation to targeted therapies.
Light lunch served
Sponsored by the UCLA Jonsson Comprehensive Cancer Center Cancer Molecular Imaging, Nanotechnology and Theranostics research program